Soporte Clínico

[1]P. J. M. a. M. B. Michael E. Johnson, «Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye,» Graefe’s Arch Clin Exp Ophthalmol, vol. 244, pp. 109-112, 2006.
[2]S. K. e. al, «Effects of Topical 1% Sodium Hyaluronate and Hydroxypropyl Methylcellulose in Treatment of Corneal Epithelial Defects,» Med Hypothesis Discov Innov Ophthalmol, vol. 5,nº 4, pp. 136-144, 2016.
[3]B. U. e. al, «Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness,» Cont Lens Anterior Eye, vol. 33, nº 2, pp. 61-67, 2010.
[4]S. S. e. al, «Viscosity-dependent fluid dynamics of eyedrops on the ocular surface,» Am J Ophthalmol, vol. 125, nº 3, pp. 386-388, 1998.
[1]M. K. K. N. E. K. A. B. C. H. S. D. C.-K. J. Z. L. J. D. N. J. J. N. Jennifer P. Craig, «TFOS DEWS II Definition and Classification Report,» The Ocular Surface, vol. 15, p. 8, 2017.
[2]A. r. o. h. a. i. o. applications, «Marjorie J. Rah,» Optometry, vol. 82, nº 1, p. 6, 2011.
[3] P. J. M. M. B. Michael E. Johnson, «Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye,» Graefe’s Arch Clin Exp Ophthalmol, vol. 244, p. 4, 2006.
 
Referencias a disponibilidad del interesado en el Departamento Médico de Scandinavia Pharma.